Literature DB >> 14518071

Hereditary nonpolyposis colorectal cancer and related conditions.

Emanuela Lucci-Cordisco1, Ilaria Zito, Francesca Gensini, Maurizio Genuardi.   

Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC) is a cancer-predisposing condition caused by inactivating mutations in at least four genes (MSH2, MLH1, MSH6, and PMS2) belonging to the mismatch repair system. At present, availability of the microsatellite instability (MSI) test allows screening of a relevant fraction of patients with a constellation of features suggestive of HNPCC. By analogy with several other genetic disorders, it is clearly emerging that the term HNPCC encompasses a wide spectrum of different clinical presentations, including Muir-Torre syndrome, Turcot syndrome, and the neurofibromatosis-hematological malignancy association. Notwithstanding the remarkable genetic and allelic heterogeneity, a few consistent phenotype-genotype associations can be recognized. Mutations in the MSH2 gene entail higher risks of developing cancer, including extraintestinal ones, than MLH1 alterations. MSH2 also accounts for most cases of Muir-Torre syndrome, which is characterized by the presence of sebaceous skin tumors. The few known PMS2 mutations show a striking association with the presence of gliomas, which are the hallmark of the Turcot variant of HNPCC. Homozygotes for mismatch repair gene mutations present with stigmata of neurofibromatosis 1 and usually die in childhood due to a variety of leukemias and lymphomas. While such correlations are being defined, the underlying reasons have only partially been elucidated, and may include heterogeneous gene functions and properties; types of mutation, some of which may exert dominant negative effects; and genetic and environmental modifiers. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14518071     DOI: 10.1002/ajmg.a.20475

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  15 in total

1.  Scram1 is a modifier of spinal cord resistance for astrocytoma on mouse Chr 5.

Authors:  Jessica Amlin-Van Schaick; Sungjin Kim; Karl W Broman; Karlyne M Reilly
Journal:  Mamm Genome       Date:  2011-12-08       Impact factor: 2.957

Review 2.  Lower gastrointestinal tract cancer predisposition syndromes.

Authors:  Neel B Shah; Noralane M Lindor
Journal:  Hematol Oncol Clin North Am       Date:  2010-12       Impact factor: 3.722

3.  Detection of germline mutations of hMLH1 and hMSH2 based on cDNA sequencing in China.

Authors:  Chao-Fu Wang; Xiao-Yan Zhou; Tai-Ming Zhang; Meng-Hong Sun; Da-Ren Shi
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

4.  An individual with Muir-Torre syndrome found to have a pathogenic MSH6 gene mutation.

Authors:  Angela Arnold; Stewart Payne; Samantha Fisher; Diane Fricker; Judith Soloway; Susan M White; Marco Novelli; Kylie MacDonald; James Mackay; Richard Groves; Natalie Canham
Journal:  Fam Cancer       Date:  2007-02-24       Impact factor: 2.375

Review 5.  Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications.

Authors:  Sara C Shalin; Stephen Lyle; Eduardo Calonje; Alexander J F Lazar
Journal:  Histopathology       Date:  2010-01       Impact factor: 5.087

Review 6.  Functional analyses of human DNA repair proteins important for aging and genomic stability using yeast genetics.

Authors:  Monika Aggarwal; Robert M Brosh
Journal:  DNA Repair (Amst)       Date:  2012-02-18

7.  Clinical phenotype and prevalence of hereditary nonpolyposis colorectal cancer syndrome in Chinese population.

Authors:  Yuan-Zhi Zhang; Jian-Qiu Sheng; Shi-Rong Li; Hong Zhang
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

8.  An unusual case of Turcot's syndrome associated with ileal adenocarcinoma, intestinal non-Hodgkin's lymphoma, and duodenal adenocarcinoma. Review of the classification and genetic basis of Turcot's syndrome.

Authors:  H R Murphy; W Taylor; A Ellis; R Sturgess
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

9.  MLH1 constitutional and somatic methylation in patients with MLH1 negative tumors fulfilling the revised Bethesda criteria.

Authors:  Francesca Crucianelli; Rossella Tricarico; Daniela Turchetti; Greta Gorelli; Francesca Gensini; Roberta Sestini; Laura Giunti; Monica Pedroni; Maurizio Ponz de Leon; Serenella Civitelli; Maurizio Genuardi
Journal:  Epigenetics       Date:  2014-10       Impact factor: 4.528

10.  A novel MSH2 germline mutation in a Druze HNPCC family.

Authors:  Jamal Zidan; Renée C Niessen; Yael Laitman; Dennie Rozeveld; Robert M W Hofstra; Eitan Friedman
Journal:  Fam Cancer       Date:  2007-07-29       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.